6,7-Dimethoxy-2-{2-[4-(1H-1,2,3-triazol-1-yl)phenyl]ethyl}-1,2,3,4-tetrahydroisoquinolines as superior reversal agents for P-glycoprotein-mediated multidrug resistance

ChemMedChem

Volumn 10, Issue 2, 2015, Pages 336-344

  Liu, Baomin ^a,b   Qiu, Qianqian ^a   Zhao, Tianxiao ^a   Jiao, Lei ^a   Li, Yunman ^a   Huang, Wenlong ^a   Qian, Hai ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

^b Drug Research Institute   (China)

Author keywords

Accumulation; Antitumor agents; Modulators; Multidrug resistance; P glycoprotein

Indexed keywords

1,2,3 TRIAZOLE DERIVATIVE; 2 [[1 [4 [2 (6,7 DIMETHOXY 3,4 DIHYDROISOQUINOLIN 2(1H) YL)ETHYL]PHENYL] 1H 1,2,3 TRIAZOL 4 YL]METHOXY] N (2 METHOXYPHENYL)BENZAMIDE; 2 [[1 [4 [2 (6,7 DIMETHOXY 3,4 DIHYDROISOQUINOLIN 2(1H) YL)ETHYL]PHENYL] 1H 1,2,3 TRIAZOL 4 YL]METHOXY] N (3 METHOXYPHENYL)BENZAMIDE; 2 [[1 [4 [2 (6,7 DIMETHOXY 3,4 DIHYDROISOQUINOLIN 2(1H) YL)ETHYL]PHENYL] 1H 1,2,3 TRIAZOL 4 YL]METHOXY] N (3,4 DIMETHOXYPHENYL)BENZAMIDE; 2 [[1 [4 [2 (6,7 DIMETHOXY 3,4 DIHYDROISOQUINOLIN 2(1H) YL)ETHYL]PHENYL] 1H 1,2,3 TRIAZOL 4 YL]METHOXY] N (4 FLUOROPHENYL)BENZAMIDE; 2 [[1 [4 [2 (6,7 DIMETHOXY 3,4 DIHYDROISOQUINOLIN 2(1H) YL)ETHYL]PHENYL] 1H 1,2,3 TRIAZOL 4 YL]METHOXY] N (M TOLYL)BENZAMIDE; 2 [[1 [4 [2 (6,7 DIMETHOXY 3,4 DIHYDROISOQUINOLIN 2(1H) YL)ETHYL]PHENYL] 1H 1,2,3 TRIAZOL 4 YL]METHOXY] N (O TOLYL)BENZAMIDE; 2 [[1 [4 [2 (6,7 DIMETHOXY 3,4 DIHYDROISOQUINOLIN 2(1H) YL)ETHYL]PHENYL] 1H 1,2,3 TRIAZOL 4 YL]METHOXY] N PHENYLBENZAMIDE; 4 CHLORO N [2 [[1 [4 [2 (6,7 DIMETHOXY 3,4 DIHYDROISOQUINOLIN 2(1H) YL)ETHYL]PHENYL] 1H 1,2,3 TRIAZOL 4 YL]METHOXY]PHENYL]BENZENESULFONAMIDE; 6,7 DIMETHOXY 2 [2 [4 (1H 1,2,3 TRIAZOL 1 YL)PHENYL]ETHYL] 1,2,3,4 TETRAHYDROISOQUINOLINE DERIVATIVE; CYTOCHROME P450 3A4; CYTOTOXIC AGENT; DOXORUBICIN; GLYCOPROTEIN P INHIBITOR; MULTIDRUG RESISTANCE PROTEIN; N (3 CHLOROPHENYL) 2 [[1 [4 [2 (6,7 DIMETHOXY 3,4 DIHYDROISOQUINOLIN 2(1H) YL)ETHYL]PHENYL] 1H 1,2,3 TRIAZOL 4 YL]METHOXY]BENZAMIDE; N [2 [[1 [4 [2 (6,7 DIMETHOXY 3,4 DIHYDROISOQUINOLIN 2(1H) YL)ETHYL]PHENYL] 1H 1,2,3 TRIAZOL 4 YL]METHOXY]PHENYL] 2 NITROBENZENESULFONAMIDE; N [2 [[1 [4 [2 (6,7 DIMETHOXY 3,4 DIHYDROISOQUINOLIN 2(1H) YL)ETHYL]PHENYL] 1H 1,2,3 TRIAZOL 4 YL]METHOXY]PHENYL] 4 FLUOROBENZENESULFONAMIDE; N [2 [[1 [4 [2 (6,7 DIMETHOXY 3,4 DIHYDROISOQUINOLIN 2(1H) YL)ETHYL]PHENYL] 1H 1,2,3 TRIAZOL 4 YL]METHOXY]PHENYL] 4 METHOXYBENZESULFONAMIDE; N [2 [[1 [4 [2 (6,7 DIMETHOXY 3,4 DIHYDROISOQUINOLIN 2(1H) YL)ETHYL]PHENYL] 1H 1,2,3 TRIAZOL 4 YL]METHOXY]PHENYL] 4 METHYLBENZESULFONAMIDE; N [2 [[1 [4 [2 (6,7 DIMETHOXY 3,4 DIHYDROISOQUINOLIN 2(1H) YL)ETHYL]PHENYL] 1H 1,2,3 TRIAZOL 4 YL]METHOXY]PHENYL]BENZESULFONAMIDE; N [4 (TERT BUTYL)PHENYL] 2 [[1 [4 [2 (6,7 DIMETHOXY 3,4 DIHYDROISOQUINOLIN 2(1H) YL)ETHYL]PHENYL] 1H 1,2,3 TRIAZOL 4 YL]METHOXY]BENZAMIDE; RHODAMINE 123; TETRAHYDROISOQUINOLINE DERIVATIVE; UNCLASSIFIED DRUG; VERAPAMIL; 2-((1-(4-(2-(6,7-DIMETHOXY-3,4-DIHYDROISOQUINOLIN-2(1H)-YL)ETHYL)PHENYL)-1H-1,2,3-TRIAZOL-4-YL)METHOXY)-N-(P-TOLYL)BENZAMIDE; ANTINEOPLASTIC AGENT; BENZAMIDE DERIVATIVE; CYTOCHROME P450 3A; CYTOCHROME P450 3A INHIBITOR; DAUNORUBICIN; PACLITAXEL; PROTEIN BINDING; TRIAZOLE DERIVATIVE; VINCRISTINE;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER RESISTANCE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG CYTOTOXICITY; DRUG DESIGN; DRUG EFFECT; DRUG METABOLISM; DRUG POTENCY; DRUG SYNTHESIS; DRUG TRANSPORT; EC50; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IC50; K562 CELL LINE; LIVER MICROSOME; MALE; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; RAT; TREATMENT DURATION; CELL SURVIVAL; CHEMISTRY; DRUG EFFECTS; DRUG RESISTANCE; METABOLISM; STRUCTURE ACTIVITY RELATION; SYNTHESIS;

ANTINEOPLASTIC AGENTS; BENZAMIDES; CELL SURVIVAL; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 CYP3A INHIBITORS; DAUNORUBICIN; DRUG RESISTANCE, NEOPLASM; HUMANS; K562 CELLS; P-GLYCOPROTEINS; PACLITAXEL; PROTEIN BINDING; RHODAMINE 123; STRUCTURE-ACTIVITY RELATIONSHIP; TETRAHYDROISOQUINOLINES; TRIAZOLES; VINCRISTINE;

EID: 84921821833     PISSN: 18607179     EISSN: 18607187     Source Type: Journal    
DOI: 10.1002/cmdc.201402463     Document Type: Article

References (19)

1. P. D. Eckford, F. J. Sharom, Chem. Rev. 2009, 109, 2989-3011.
2. A. Breier, L. Gibalova, M. Seres, M. Barancik, Z. Sulova, Anti-Cancer Agents Med. Chem. 2013, 13, 159-170.
3. K. Wong, J. Ma, A. Rothnie, P. C. Biggin, I. D. Kerr, Trends Biochem. Sci. 2014, 39, 8-16.
4. C. Martelli, D. Alderighi, M. Coronnello, S. Dei, M. Frosini, B. Le Bozec, D. Manetti, A. Neri, M. N. Romanelli, M. Salerno, J. Med. Chem. 2009, 52, 807-817.
5. C. Baumert, A. Hilgeroth, Anti-Cancer Agents Med. Chem. 2009, 9, 415-436.
6. A. Palmeira, E. Sousa, M. H. Vasconcelos, M. M. Pinto, Curr. Med. Chem. 2012, 19, 1946-2025.
7. L. Zhang, S. Ma, ChemMedChem 2010, 5, 811-822.
8. a) B. Liu, Q. Qiu, T. Zhao, L. Jiao, J. Hou, Y. Li, H. Qian, W. Huang, Chem. Biol. Drug Des. 2014, 84, 182-191;
9. b) V. Jekerle, W. Klinkhammer, D. A. Scollard, K. Breitbach, R. M. Reilly, M. Piquette-Miller, M. Wiese, Int. J. Cancer 2006, 119, 414-422.
10. I. L. Wong, K.-F. Chan, K. H. Tsang, C. Y. Lam, Y. Zhao, T. H. Chan, L. M. C. Chow, J. Med. Chem. 2009, 52, 5311-5322.
11. H. Thomas, H. M. Coley, Cancer Control 2003, 10, 159-159.
12. M. M. Gottesman, I. Pastan, Annu. Rev. Biochem. 1993, 62, 385-427.
13. C. Wandel, R. B. Kim, S. Kajiji, F. P. Guengerich, G. R. Wilkinson, A. J. Wood, Cancer Res. 1999, 59, 3944-3948.
14. S. Jabbar, P. Twentyman, J. Watson, Br. J. Cancer 1989, 60, 523.
15. K.-F. Chan, I. L. Wong, J. W. Kan, C. S. Yan, L. M. Chow, T. H. Chan, J. Med. Chem. 2012, 55, 1999-2014.
16. B. S. Ji, L. He, J. Pharm. Pharmacol. 2007, 59, 1011-1015.
17. A. H. Dantzig, R. L. Shepard, J. Cao, K. L. Law, W. J. Ehlhardt, T. M. Baughman, T. F. Bumol, J. J. Starling, Cancer Res. 1996, 56, 4171-4179.
18. M. M. Bradford, Anal. Biochem. 1976, 72, 248-254.
19. P. Kuehl, J. Zhang, Y. Lin, J. Lamba, M. Assem, J. Schuetz, P. B. Watkins, A. Daly, S. A. Wrighton, S. D. Hall, Nat. Genet. 2001, 27, 383-391.